業績

2014年度 :: 学会発表 :: 国際学会 :: 業績

25th Conference of the Asia Pacific Association for the Study of the Liver (APASL 2015)
2015.3. Istanbul, Turkey


Karino Y, Suzuki F, Suzuki Y, Toyota J, Chayama K, Kawakami Y, Fujiyama S, Ito T, ltoh Y, Tamura E, Ueki T, Ishikawa H, Linaberry M, Hughes E, Kumada H.
All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected wjth HGV Genotype 1 b: The Al447031 Study.

Tsunematsu S, Ito J, Sato F, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N.
Hepatitis b virus x protein impairs alpha interferon signaling through up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2a.

2015 Gastrointestinal Cancers Symposium(ASCO-GI 2015)
2015. 1. San Francisco, USA


Hatanaka K, Yuki S, Nakatsumi H, Fukushima H, Naruse H, Kato T, Meguro T, Nakamura M, lwanaga I, Uebayashi M, Tateyama M, 日o K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Komatsu Y.
Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Comparison of infusional FU/ Oxaliplatin(OX)+BV and oral FU/OX+BV.

Hosokawa A, Yuki S, Nakatsumi H, Hatanaka K, Tsuji Y, Okuda H, Takahashi Y, Konno J, Eto K, Kawamoto Y, Sonoda N, Sato Y, Saito M, Miyagishima T, Ikeda S, Yoshizaki K, Sasaki T, Saitoh S, Sakata Y, Komatsu Y.
Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901.

Komatsu Y, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto 0, Meguro T, lwanaga I, Hatanaka K, Tsuji Y, Sato A, Eta K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Sakata Y.
Phase II trial of lrinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Get) as second line treatment in patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. -Comparison of administration interval in Cetuximab treatment.

Muro K, Bodoky G, Cesas A, Chao Y, Clingan P, Hironaka S, Komatsu Y, Kurteva PG, Lipatov ON, Nishina丁,Oh SC, Ohtsu A, Shimada Y, Sugimoto N, Van Cutsem E, Carlesi R, Chandrawansa K, Wilke H.
RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastr ic and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy-An age-group analysis.

Nakamura M.
An Observational study of a team management approach for first-line XELOX therapy in patients with advanced/recurrenct colorectal cancer.

Nakatsumi H, Yuki S, Muranaka T, Fukushima H, Kato T, Meguro T, Nakamura M, lwanaga I, Ehira N, Sonoda N, Kudo M, Kato K, Miyashita K, Abe M, Sakamoto K, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y.
Association of Early Tumor Shrinkage with Progression Free Survival in Patients with Metastatic Colorectal Cancer treated with Bevacizumab-based Chemotherapy: HGCSG0802.

Nomura M, Kato K, Mizusawa J, Kataoka K, Ando N, Muro K, Ohtsu A, lgaki H, Shinoda M, Takeuchi H, Shimizu H, Hayashi K, Daiko H, Goto M, Komatsu Y, Konishi K, Miyata Y, Kitagawa Y.
Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage 11-111 esophageal squamous cell carcinoma (ESCC) (JCOG1406-A),

Shitara K, Fujii S, Denda T, Kajiwara T, Yuki S, Nakajima T, Takashima A, Kawasaki K, Tamura T, Esaki T, Naruge D, Ebi H, Kudo T, Taniguchi H, Akagi K, Yamanaka T, Ochiai A, Doi T, Ohtsu A, Yoshino T.
The Nationwide Genomic Screening Project for Gastro-intestinal Cancer in Japan (GI-SCREEN): Simultaneous Identification of KRAS, NRAS, BRAF and PIK3CA Mutation in Advanced Colorectal Cancer (aCRC) (GI-SCREEN 2013- 01).

Sogabe S, Yuki S, Fukushima H, Takahashi N, Shichinohe T, Kusumi T, Nakamura F, lwanaga I, Hatanaka K, Miyashita K, Konno J, Uemura K, Nenohi M, Kina M, Sakamoto N, Taketomi A, Hirano S, Amano T, Ito Y, Komatsu Y.
Safety analysis of FOLFOX as adjuvant chemotherapy for stage Ill colon cancer in phase II study (NORTH/ HGCSG 1003) - Detailed analysis of peripheral sensory neuropathy.

Takahata T, Yuki S, Nakatsumi H, Harada K, Fukushima H, Sato A, Kato T, Meguro T, Nakamura M, Ehira N, lwanaga I, Tateyama M, Hatanaka K, Eta K, Okuda H, Kobayashi Y, Muto 0, Abe M, Sakata Y, Komatsu Y.
Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by KRAS Exon2 Status.

Yagisawa.M, Sogabe S, lwanaga I, Oshino T, Yamamura T, Hirata H, Nakajima M, Suzuki K, Shimano J, Takasaka T, Takahashi K, Kobayashi Y, Kudo T, Okada K, Dazai M, Oda H, Miyagishima T.
Weekly nanoparticle albumin-bound paclitaxel(nab-PTX) as second-or later-line treatment for unresectable or recurrent gastric cancer in practice.

Yamazaki K, Yoshino T, Tsuchihara K, Shinozaki E, Muro K, Nishina T, Yamaguchi K, Akagi K, Yuki S, Yamanaka T, Nomura S, Fujii S, Esumi H, Abe Y, Ohtsu A.
Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: an analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).

Yuki S, Nakatsumi H, Hayashi H, Fukushima H, Kato T, Meguro T, Nakamura M, lwanaga I, Eto K, Sato A, Okuda H, Oba A, Miyagishima T, Muto 0, Yabusaki S, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y.
Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.

The 65th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD2014)
2014.11. Boston, USA


Hige S, Ozeki I, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Karino Y, Toyota J, Mizokami M , Narimatsu H.
Evaluation of liver fibrosis and prediction of hepatic carcinogenesis for patients with chronic hepatitis B by a unique glycoprotein: Wisteria floribunda agglutinin-positive Mac-2 binding protein 0f\/FA+-M2BP).

Karino Y, Hige S, Nakajima T, Kimura M, Arakawa T, Kuwata Y, Sato T, Ohmura T, Toyota J.
Analysis of the liver function and hepatic reserve improvement effect, and liver carcinogenesis suppressant effect of the Daclatasvir/Asnaprevir combination therapy.

Huong T.L.T, Morikawa K, Rose Z, Dao Thi VL, Penin F, Markus H. Heim MH, Quadroni M, Goittenoire J, Darius M.
Identification of OCIAD1 as Cellular Substrate of the HCV NS3-4A Protease.

Nakai M, Seya T, Matsumoto M, Hussein H Aly, Sho T, Ogawa K, Sakamoto N.
Characterization of a lymphotropic HCV-J6JFH1 replication in human primary B cells.

Natsuizaka M, Maehara 0, Sato F, Kubota Y, Suda Goki, ltoh J, Tsunematsu S, Tsukuda Y, Terashita K, Nakai M, Sha T, Ogawa K, Ohnishi S, Sakamoto N.
A pivotal role of KLF5 in regulation of cancer stem-like cells in hepatocellular carcinoma.

Suda G, Tsukuda Y, Tsunematsu S, Satou F, Terasita K, Sho T, Nakai M, Natsuizka M, Morikawa K, Ogawa Kouji, Sakamoto N.
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reaction.

Tran HT, Morikawa K, Rose Z, Dao Thi VL, Penin F, Heim MH, Quadroni M, Goittenoire J, Moradpour D.
Identification of OCIAD1 as Cellular Substrate of the HGV NS3-4A Protease.

The 11th JSH Single Topic Conference
2014. 11. Hiroshima, Japan


Hige S, Ozeki I, Yamaguchi M, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Karino Y, Toyota J.
Risk of hepatocellular carcinoma for Hepatitis B patients with nucleoside analogues by the estimation of fibrosis index at the start of the treatment.

Shimazaki T, Date T, Gouttenoire J, Quadroni M, Moradpour D, Morikawa K.
The Hepatitis B virus modulates cellular factors in the direction of slowdown or stop cell cycle and proliferation.

Suda G, Tsukuda Y, Tsunematsu S, Sato F, Terasita K, Sho T, Nakai M, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
COOH-truncated Hepatitis B virus X protein up-regulates CD44+ cancer stem like cells via LTBP1.

22nd United European Gastroenterology Week (UEGW2014)
2014.10. Vienna, Austria


Matsuoto M, kato M, Sakamoto N.
Multicenter randomized controlled study to assess the preventive effect of prophylactic clipping for post-poypectomy bleeding.


Kubo K, Ohnishi S, Sakamoto N.
Human amni on-derived mesenchymal stem cell transplantation ameliorates liver fibrosis induced by CCl4 in rats.

Sato T.
Ectopic varices with portal hypertension.

The 8th Meeting of the Society of Gastrointestinal Intervention (SGI 2014)
2014.10. Seoul, Korea


Kawakubo K. Kawakami H, Kuwatani M, Abe Y, Kawahata S, Kubota Y, Kubo K, Sakamoto N.
EUS-guided choledochoduodenostomy with a conventional metallic stent: outcome of a single center experience.

Kuwatani M, Kawakami H, Kawakubo K, Abe Y, Kawahata S, Kubo K, Sakamoto N.
EUS -guided antegrade biliary dilation with a diathermic dilator.

EUS2014 -19th International Symposium on Endoscopic U ltrasonography
2014.9. Chennai, India


Haba S, Yoshii S, Kawamoto Y, Shimizu S, Hayashi K, Yokoyama A, Akakura N.
Clinical features of early chronic pancreatitis detected by EUS.

European Cancer Congress 2014 (ECC2014)
2014.9. Madrid, Spain


Nakamura M.
Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer.

Fukushima H, Yuki S, Nakatsumi H, Hayashi H, Harada K, Muranaka T, Nakamura M, Kawamoto Y, Kobayashi Y, Miyagishima T, Sogabe S, Tateyama M, Eto K, Hatanaka K, lshiguro A, Okuda H, Takahashi Y, lwanaga Y, Sakata Y, Komatsu Y.
Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment (HGCSG1301).

HCV Meeting2014 (21st International Symposium on Hepatitis C and Related Viruses)
2014.9. Banff, Canada


Morikawa K, Rose Z, Dao Thi VL, Penin F, Heim MH, Donze 0, Ouadroni M, Gouttenoire J, Moradpour D.
Identification of OCIAD1 as Cellular Substarate of HGV NS3- 4A Protease. 21th International Symposium on Hepatitis C Virus and Related Viruses

Tsukuda Y, Ito J, Tsunematsu S, Sato F, Terashita K, Nakai M, Sha T, Suda G, Ogawa K, Sakamoto N.
Anti-ad1pogenic and Anti-viral Effect of L-carnitine on Hepatitis C Virus Infection.

EHSG2014
2014.9. Rome, Italy


Mabe K, Miyamoto S, Mizushima T, Ono M, Omori S, Ono S, Shimizu Y, Kato M, Asaka M.
The strategy of test and treat for H.pylori infection to junior and senior high school students in Hokkaido, Japan.

Ono S, Mabe K, Kato M, Sakamoto N.
Recovery of serum pepsinogen after eradication of Helicobacter pylori in subjects with peptic ulcer: 10-year follow-up study.

The 39th European Society for Medical Oncology Congress (ESM02014)
2014.9. Madrid, Spain


Fukushima H, Yuki S, Nakatsumi H, Hayashi H, Harada K, Muranaka T, Nakamura M, Kawamoto Y, Kobayashi Y, Miyagishima T, Sogabe S, Tateyama M, Eto K, Hatanaka K, lshiguro A, Okuda H, Takahashi Y, lwanaga I, Sakata Y, Komatsu Y.
Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment (HGCSG1301).

Hayashi H, Kohno T, Hiraoka N, Sakamoto Y, Kondo S, Morizane C, Saito M, Shimada K, Ichikawa H, Komatsu Y, Ueno H, Okusaka T.
Gene mutation profile of pancreatic cancer obtained using targeted deep sequencing and its association with prognosis.

Muto 0, Yuki S, Fukushima H, Nakamura M, Hosokawa A, Kato T, lwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y.
First report of a phase II trial of lrinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Get) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902.

Nakamura M, Kobayashi Y, Yuki S, Nakatsumi H, Hayashi H, lwanaga I, Tsuji Y, Hatanaka K, Okuda H, Konno J, Yamamoto F, lwai K, Onodera M, Takagi T, Hisai H, Koike M, Abe R, Oba K, Sakata Y, Komatsu Y.
Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Additional analysis of OOL and skin toxicity.

Shinozaki E, Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Sasaki T, Shitara K, Nagatsuma A, Yoshino T, Ochiai A, Ohtsu A.
Prognostic impact of HER2, EGFR, and c-MET status on overall suivival of advanced gastric cancer patients treated with standard chemotherapy without trastuzumab in a first-line treatment: a Japanese multicenter collaborative retrospective study.

The 4th International Kyoto Liver Cancer Symposium
2014.6. Kyoto, Japan


Hige S, Karina Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ozeki I, Sato T, Ohmura T, Toyota J.
Estimation of Hepatocellular Carcinoma for Patients with HBV Infection by HBs Antigen and FIB-4 Index.

16th World Congress on Gastrointestinal Cancer
2014.6. Barcelona, Spain


Yoshino T, Mayer R, Falcone A, Ohtsu A, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Benedetti F, Aivado M, Makris L, Ito M, Van Cutsem E.
Results of a multicenter, randomised, double-blind, phase Ill study of TAS-102 vs. placebo, with best supportive care (BSC), in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies (RECOURSE)


Yuki S, Komatsu Y, Harada K, Fukushima H, Sasaki T, Kobayashi Y, Tsuji Y, Naruse H, Okuda H, Takahashi Y, Hosokawa A, Konno J, Eto K, Kudo K, Kawamoto Y, Sonoda N, Sato Y, Uebayashi M, Kato T, Onodera M, Ohta T, Sakata Y.
Analysis of Glasgow Prognostic Score(GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.

Takahashi N, Yuki S, Fukushima H, Sh1chinohe T, Sasaki T, Kusumi T, Nakamura F, Miyagishima T, lwanaga I, Hatanaka K, Oomori K, Misawa K, Senmaru N, lwai K, Koike M, Shinohara T, Fukushima T, Ohno K, Tateyama M, Nishimoto N, Ito Y, Komatsu Y.
Safety analysis of FOLFOX as adjuvant chemotherapy for stage Ill colon cancer 1n North Japan multicenter phase II study (NORTH/HGCSG1003).

MASCC/1S00 International Symposium
2014.6. Miami, USA


lsobe H, Yuki S, Furuhata T, Sagawa T, Masuko H, Hatanaka K, Miyagishima T, Sasaki K, Nakamura M, Sasaki T, Nakajima J, Tateyama M, Yokoyama R, Minami S, Eto K, lwanaga I, Shibuya H, Kudo M, Oba K, Komatsu Y.
A randomized phase Ill trial of palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting induced by non-AC MEC: HOPE-01.

T-CAP2014
2014.6. Tokyo, Japan


Kawakubo K, Kawakami H, Kuwatani M, Abe Y, Kudo T, Kubo K and Sakamoto N.
Feasibility of single-step simultaneous side-by-side placement using 6Fr self-expandable metallic stent.

2014 ASCO Annual Meeting
2014.5. Chicago, USA


Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima T, Lizambri R, Loh E, Tang R, Zhang Y, Yasui H.
Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with M笆。 ?☆positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Kobayashi Y, Komatsu Y, Yuki S, Nakatsumi H, Fukushima H, Miyagishima T, Ehira N, lwanaga I, Okuda H, Kusumi T, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Takagi T, Hisai H, Abe R, Oba K, Sakata Y.
Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP). - Additional report of the efficacy analyses.

Digestive Disease Week 2014 (DDW 2014)
2014.5. Chicago, USA


Kato M, Kikuchi S, Asaka M. for the Japan Gast Study Group.
Long-term follow-up study about preventive effect of H. pylori eradication for the incidence of metachronous gastric cancer after endoscopic resection of primary early gastric cancer.

Shimizu Y, Oda I, Yoshio T, Katada C, Yokoyama T, Kaneko K, Doyama H, Koike T, Takizawa K, Okada H, Yoshii T, Konishi K, Yamanouchi T, Tsuda T, Omori T, Kobayashi N, Hirao M, Shimoda T, Ochiai A, Ishikawa H, Yokoyama A, Muto M.
Long-term outcomes of endoscopic resection for early-stage esophageal squamous cell neoplasms: a multicenter prospective study.


Kobayashi Y.
Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab : J-STEPP).

Kuwatani M, Kawakami H, Hayashi T, Eto K, Yamato H, Onodera M.
Effect of antispasmodic drugs on endosco pic ultrasonography/endoscopic ultrasound-guided fine-needle aspiration: a multicenter, prospective randomized controlled trial.

Kawakubo K, Kawakami H, Kuwatani M, Abe Y, Kawahata S, Kubota Y, Kubo K, Sakamoto N.
Feasibility of single-step simultaneous side-by-side placement using 6Fr self-expandable metallic stent.

Kawakubo K, Kawakami H, Kuwatani M, Abe Y, Kawahata S, Kubota Y, Kubo K, Sakamoto N.
Risk factors for technical failure of endoscopic multiple metallic stent placement by stent-in-stent method for unresectable malignant hilar biliary obstruction.

Natsuizaka M, Kaimila B, Kubota Y, Hatanaka Y, Marukawa K, Terashita K, Sato F, Ohnishi S, Suda G, Ohashi S, Kagawa S, Whelan K, Rustgi AK, Nakagawa H, Sakamoto N.
EGFR inhibitors eliminate esophageal cancer stem cells by suppressing epithelial-mesenchymal transition.

Ohnishi S, Muto S, Nakagawa K, Yamada C, Saegusa Y, Nahata M, Sadakane C, Hattori T. Sakamoto N, Takeda H.
Gender difference influences food intake under an emotional stress via 5-HT2CR activation in aged mice.

Sato T.
Treatment for rectal variceal bleeding with portal hypertension.

Yoshii S, Watano K, Akakura N.
A Comparison of lmmunochemical Fecal Occult Blood Test and Total Colonoscopy in an Asymptomatic Population.

The 11th International Conference of the Asia Clinical Oncology Society
2014.5. Taipei, Taiwan


Nakamura M, Yuki S, Okita K, Sato Y, Abe M, Hatanaka K, lsobe H, Dazai M, Ohno K, Sasaki T, Noji T, Tateyama M, Yokoyama R, Minami S, Eto K, lwanaga I, Shibuya H, Kudo M, Oba K, Komatsu Y.
A Randomized Phase III Trial of Palonosetron Plus Dexamethasone (day 1) Versus Palonosetron Plus Dexamethasone (day1-3) in the Prevention of Nausea and Vomiting induced by Moderately Emetogenic Chemotherapy, not including a combination of anthracycline plus cyclophosphamide: Hokkaido supportive care Oncology Project in Expert group (HOPE)-01.

>